Boehringer
Found 7 free book(s)HIGHLIGHTS OF PRESCRIBING ... - Boehringer Ingelheim
docs.boehringer-ingelheim.com150 mg capsules: brown, opaque, oblong, soft capsules imprinted in black with the Boehringer Ingelheim company symbol and "150". 100 mg capsules: peach, opaque, oblong, soft capsules imprinted in black with the Boehringer Ingelheim company symbol and "100". 4 CONTRAINDICATIONS None 5 WARNINGS AND PRECAUTIONS 5.1 Hepatic Impairment
Practice Parameters for Clinical Use of the Multiple Sleep ...
aasm.orgGlaxoSmithKline, Boehringer-Ingelheim, and Novartis; and is or has recently been a consultant for GlaxoSmithKline, Astrazeneca, Pfizer, Novartis, Boehringer-Ingelheim, Otsuka. Dr. Hirshkowitz is a member of the speakers’ bureau for Sanofi and Cephalon; and has received hono-raria from Sanofi and Cephalon. Dr. Bailey is a partner in Dental
HIGHLIGHTS OF PRESCRIBING ... - Boehringer Ingelheim
docs.boehringer-ingelheim.com3 full prescribing information warning: (a) premature discontinuation of pradaxa increases the risk of thrombotic events, and (b) spinal/epidural hematoma
PredniSONE Tablets USP, 1 mg, 2.5 ... - Boehringer Ingelheim
docs.boehringer-ingelheim.comC 21 H 26 O 5 M.W. 358.43 Prednisone is a white to practically white, odorless, crystalline powder. It is very slightly soluble in water; slightly soluble in …
Clinical Trial Protocol
www.clinicaltrials.govBoehringer Ingelheim Name of finished product: Not applicable Name of active ingredient: BIBF 1120 (nintedanib) Protocol date: Trial number: Revision date: 27 Jan 2012 1199.33 28 Mar 2017 Title of trial: An open-label extension trial of the long term safety oforal BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) Co-ordinating ...
Assessment report - European Medicines Agency
www.ema.europa.euBoehringer Ingelheim Pharma GmbH & Co. KG Binger Strasse 173 55216 Ingelheim am Rhein Germany 1.3. Steps taken for the assessment of the product The Rapporteur and Co-Rapporteur appointed by the CHMP: Rapporteur: Pieter de Graeff Co-Rapporteur: Bart Van der Schueren • The application was received by the EMA on 5 March 2013.
Boehringer Ingelheim
docs.boehringer-ingelheim.comFULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Maintenance Treatment of Chronic Obstructive Pulmonary Disease SPIRIVA RESPIMAT (tiotropium bromide) is indicated for the long-term, once-daily, maintenance tr eatment of …